GlassScriptPhysician profile
Alexander E Tzouanakis
NPI 1700890506
$5,180.14
in general payments reported to CMS, 2019-2025
42 companies · $1,277 in 2025
The $1,277 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $328 · 2021: $396 · 2022: $344 · 2023: $1,094 · 2024: $693 · 2025: $1,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,853 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,853.13 |
| Education | $211.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $553.65 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $453.66 | 2019-2025 | Ofev, Jascayd |
| Jazz Pharmaceuticals INC. | $448.06 | 2019-2025 | |
| Genentech USA, INC. | $358.97 | 2019-2023 | Xolair |
| Grifols USA, LLC | $345.32 | 2019-2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $278.07 | 2023-2024 | Sunosi |
| Harmony Biosciences LLC | $264.54 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $250.45 | 2019-2025 | Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $203.67 | 2022-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $194.72 | 2019-2023 | Uptravi, Opsumit |
| Insmed, INC. | $154.81 | 2024-2025 | Arikayce |
| Gilead Sciences, INC. | $151.18 | 2019-2024 | Veklury |
| Abbvie INC. | $147.55 | 2022-2023 | Teflaro |
| Idorsia Pharmaceuticals US INC | $141.03 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $127.10 | 2019-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Tzouanakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.